Head-to-head evidence
albuterol HFA (Armstrong's) vs fenoterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol HFA (Armstrong's)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00635505 · Phase 3 · terminated
This is a randomized, quadruple-blind, placebo- and active-controlled study with an adequate sample size measuring lung function directly, but no results have been posted yet, so the outcome is unknown.
fenoterol
Developed by Boehringer Ingelheim
NCT02177370 · Phase 3 · terminated
This was a randomized, double-blind, active-controlled crossover study, but it enrolled only 19 participants and one of its two primary measures is a laboratory receptor-density biomarker rather than a direct asthma outcome, and no results have been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol HFA (Armstrong's)'s landscape · fenoterol's landscape